<DOC>
	<DOCNO>NCT03017651</DOCNO>
	<brief_summary>This protocol determine pK profile two different omega-3 fatty acid supplement plasma EPA DHA level .</brief_summary>
	<brief_title>An Evaluation Omega-3 Fatty Acid</brief_title>
	<detailed_description>This protocol assess omega-3 blood level DHA EPA follow single dose administration study product mean pharmacokinetics 24 hour period time ( post-dose ) .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female subject 18 65 year old ( inclusive ) 2 . Body Mass Index ( BMI ) 25.0 34.9 kg/m2 ( inclusive ) Screening . 3 . Subjects normal moderately elevate lipidemia ( borderline lipid define AACE Total cholesterol ≤ 240 mg/dl ; LDL ≤ 160 mg/dl ; TG ≤ 199 mg/dl ) . 4 . Subjects clinically significant finding physical examination , medical history , vital sign , clinical laboratory test ( hematology serum chemistry ) result deem Investigator . 5 . Subjects must understand agree comply requirement study must willing sign inform consent indicate voluntary consent participate study prior initiation Screening study related activity . 6 . Male female subject childbearing potential must agree use one follow medically acceptable contraceptive method duration study : samesex partner ; double barrier ( condom , diaphragm cervical cap spermicidal foam , gel cream ) ; IUD ( without hormone ) place hormonal contraception ( oral , injectable , implantable , transdermal vaginal ) use consecutively least 3 month prior study product administration ; vasectomized partner sterilization bilateral insertion Essure® similar product 6 month minimum prior study product administration ; bilateral tubal ligation , hysterectomy and/or bilateral oophorectomy ; postmenopausal amenorrhea least 1 year prior study product administration 1 . Currently use fish oil capsule ( supplement prescription product ) . 2 . Regular use omega3 supplement ( define great 500 mg/week ) within 4 week study product administration . 3 . Currently use medication may impact dietary fat absorption ( i.e. , Orlistat , Alli , etc. ) . 4 . Currently use medication may interfere omega3 uptake ( i.e . blood thin medication anticoagulant ) . 5 . Currently use lipid lower medication ( i.e . cholesterol triglyceride lower agent ) . 6 . Currently consume high amount EPA &amp; DHA diet ( define great 200 mg/day FFQ ) 7 . Currently follow selfreported nofat ultrarestrictive ( less 15 % ) LowFat Diet 8 . Having follow medical condition : i. Malabsorptive disorder include limited pancreatitis , Crohn 's disease , etc . ii . Hypertriglyceridemia ( define Inclusion per PI discretion ; Total cholesterol &gt; 240 mg/dl ; LDL &gt; 160 mg/dl ; TG &gt; 199 mg/dl ) iii . Type2 Diabetes Mellitus 9 . Currently smoker nicotine user nicotine free less 6 month 10 . Use systemic medication , include OTC medication , herbal product , dietary supplement vitamin ( previously list ) within 1 week study product administration ( occasional use OTC analgesic acetaminophen may allow judged Investigator ) 11 . Evidence history allergic adverse response either study product , product excipients comparable similar product 12 . Subjects willing able comply schedule visit requirement study protocol . 13 . Female subject breastfeed , pregnant plan become pregnant study . 14 . Current employee immediate family member study sponsor study site personnel . 15 . Currently participate participate another clinical trial within 4 week study product administration 16 . Donated blood , blood component , significant loss blood within 30 day study product administration 17 . History clinicallysignificant illness within 4 week study product administration 18 . History hospitalization treatment clinicallysignificant drug alcohol use/abuse within 1 year dosing . 19 . Subject poor venous access difficulty swallow capsule 20 . Any issue , judgment Investigator , make subject ineligible study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>